Celldex Therapeutics (CLDX) Return on Sales (2010 - 2026)

Celldex Therapeutics' Return on Sales history runs 17 years deep, the most recent figure standing at 52.46% for Q1 2026.

• In Q1 2026, Return on Sales fell 5168.0% year-over-year to 52.46%; the TTM figure through Mar 2026 stood at 3.28% (down 304.0% YoY), while the FY2025 annual figure was 1.67%, down 145.0% from the prior year.
• Return on Sales was 52.46% for Q1 2026 at Celldex Therapeutics, down from 6.72% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.1% in Q4 2023 to a low of 52.46% in Q1 2026.
• Historically, Return on Sales has averaged 4.15% across 5 years, with a median of 0.77% in 2025.
• The sharpest annual moves came in 2025 and 2026: Return on Sales soared 133 bps in 2025, then sank 5168 bps in 2026.
• A 5-year view of Return on Sales shows it stood at 0.16% in 2022, then surged by 36 bps to 0.1% in 2023, then tumbled by 282 bps to 0.4% in 2024, then tumbled by 1577 bps to 6.72% in 2025, then sank by 681 bps to 52.46% in 2026.
• The last three Return on Sales figures came in at 52.46% (Q1 2026), 6.72% (Q4 2025), and 0.86% (Q3 2025), per Business Quant data.